July 16, 2021
Graphic Courtesy of Avidity Biosciences
Avidity Biosciences develops RNA therapies and drugs to treat muscular disorders and other rare diseases.
Stories this photo appears in:
BIOTECH: Sarah Boyce Speaks About Completely Virtual IPO Process
The past year has changed everything about what it means for a biotech company to go public, according to Avidity Biosciences President and CEO Sarah Boyce.